Acorda
Acorda (NASDAQ: ACOR)

Acorda develops therapeutic products for spinal cord injury and other central nervous system disorders. (IPO February 2006.)

Athenix
Athenix

Athenix develops and commercializes high-value genetic traits from microbes for use in agricultural products. (Acquired by Bayer Crop Sciences in November 2009.)

Cempra Pharmaceuticals
Cempra Pharmaceuticals

Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both Phase 3-ready, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
Listed on NASDAQ February 2012 and trading under the symbol CEMP.

MacroGenics
MacroGenics

MacroGenics is focused on the development of improved immunotherapeutic products and the identification of new targets for the treatment of cancer, autoimmune disorders, allergies or infectious diseases.

Morphotek
Morphotek

Morphotek develops therapeutic monoclonal antibodies for the treatment of cancer, inflammatory and infectious diseases. (Acquired by Eisai Pharmaceuticals in April 2007.)

Myogen
Myogen

Myogen is engaged in the discovery and development of drugs for the treatment of heart failure and related cardiovascular conditions. (IPO 2003; acquired by Gilead Sciences in 2006.)

OvaScience
OvaScience

OvaScience is a privately held fertility company focused on the discovery, development and commercialization of novel treatments for infertility.
Listed on NASDAQ April 2013 and trading under the symbol OVAS.

Revance
Revance

Revance Therapeutics, Inc. is a privately held biopharmaceutical company developing the first topically applied botulinum toxin type A—one of the world's most recognized drugs.

Salmedix
Salmedix

Salmedix develops oncology drugs with an initial emphasis on hematologic cancers. (Acquired by Cephalon in 2005.)

Sirtris
Sirtris

Sirtris develops novel treatments for metabolic disease with a focus on sirtuin enzymology. (IPO 2007; acquired by GSK in April 2008.)

Synageva
Synageva

Synageva is a clinical-stage biopharmaceutical company dedicated to discovering, developing and delivering therapies for patients with rare conditions and unmet medical needs.
Listed on NASDAQ November 2011 and trading under the symbol GEVA.